(2S,4R)-4-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid | 48113-66-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-4-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid
• 英文别名: (2S,4R)-2-Carboxy-4-hydroxy-1,1-dimethyl-pyrrolidinium
• CAS: 48113-66-2
• 化学式: C₇H₁₄NO₃
• 分子量: 160.193
• InChiKey: MUNWAHDYFVYIKH-RITPCOANSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S,4R)-4-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid 、 N-[3-chloro-4-(piperazine-1-carbonyl)phenyl]-5-[3-fluoro-4-[1-(2-methoxyethyl)-5-methylpyrazol-4-yl]-2-methylphenyl]-1-methylimidazole-2-carboxamide 、 三氟乙酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以14.6 mg的产率得到N-[3-chloro-4-[4-[(2S,4R)-4-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carbonyl]piperazine-1-carbonyl]phenyl]-5-[3-fluoro-4-[1-(2-methoxyethyl)-5-methylpyrazol-4-yl]-2-methylphenyl]-1-methylimidazole-2-carboxamide 2,2,2-trifluoroacetate
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS
  [FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION EN TANT QU'ANTIBIOTIQUES

  摘要：

  The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1to R4, and R6to R10are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  公开号：

  WO2023285497A1
• 作为产物：
  描述：

  N,N′-二异丙基-O-甲基异脲 、 L-羟基脯氨酸 以 甲醇 为溶剂， 生成 (2S,4R)-4-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS
  [FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION EN TANT QU'ANTIBIOTIQUES

  摘要：

  The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1to R4, and R6to R10are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  公开号：

  WO2023285497A1

文献信息

• Treatment of Energy Utilization Disease
  申请人：Nash Robert James

  公开号：US20110015226A1

  公开（公告）日：2011-01-20

  Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.
• TREATMENT OF ENERGY UTILIZATION DISEASE
  申请人：Summit Corporation PLC

  公开号：US20160151341A1

  公开（公告）日：2016-06-02

  Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.